심부전 진단 시장 : 전략적 인사이트 및 예측(2026-2031년)

The Heart Failure Diagnostics Market is forecast to grow at a CAGR of 9.5%, reaching USD 24.35 billion in 2031 from USD 10.78 billion in 2026.

The global heart failure diagnostics market is undergoing a significant transformation, driven by the rising prevalence of cardiovascular disease and the shift toward integrated, biomarker-guided diagnostic pathways. This market encompasses diagnostic instruments, laboratory assays, imaging systems, software platforms, and clinical services designed to detect and evaluate heart failure. Diagnostic evaluation includes measurement of circulating cardiac biomarkers, assessment of cardiac structure and function through imaging technologies, and continuous monitoring of disease progression. Demand is increasing because heart failure remains one of the leading causes of hospitalization among older adults worldwide, while demographic aging and increasing prevalence of hypertension, diabetes, obesity, and coronary artery disease continue expanding the at-risk population. Clinical examination alone frequently lacks sufficient specificity during early disease presentation, increasing dependence on biomarker testing and advanced imaging for timely diagnosis. Regulatory agencies and professional cardiovascular societies continue supporting standardized diagnostic algorithms that incorporate natriuretic peptide testing and evidence-based imaging modalities. These structural changes position heart failure diagnostics as an essential component of modern cardiovascular care.

Market Drivers

Rising Global Burden of Heart Failure

• Heart failure represents one of the most significant cardiovascular diseases affecting healthcare systems worldwide because aging populations and increasing prevalence of hypertension, ischemic heart disease, diabetes, and obesity continue expanding the patient population. Demand is increasing for accurate diagnostic solutions as clinicians seek to identify heart failure before irreversible cardiac dysfunction develops. Conventional clinical assessment provides limited certainty during early disease stages, creating greater reliance on laboratory biomarkers and advanced cardiac imaging. Healthcare providers are expanding diagnostic capacity to improve early intervention and reduce recurrent hospitalizations. This structural shift strengthens long-term demand for comprehensive heart failure diagnostics.

Increasing Clinical Adoption of Natriuretic Peptide Testing

• Natriuretic peptide testing forms the cornerstone of modern heart failure diagnosis because BNP and NT-proBNP biomarkers provide objective evidence of cardiac stress and ventricular dysfunction. Clinical guidelines recommend biomarker assessment for patients presenting with symptoms suggestive of heart failure, increasing routine utilization across emergency departments and outpatient cardiology services. Diagnostic laboratories are expanding automated immunoassay platforms to accommodate higher testing volumes while improving analytical consistency. Standardized biomarker interpretation supports more confident clinical decision-making and strengthens evidence-based cardiovascular care.

Expansion of Advanced Cardiac Imaging

• Cardiac imaging provides essential information regarding ventricular function, structural abnormalities, and disease severity that cannot be obtained through laboratory testing alone. Healthcare institutions are investing in echocardiography, cardiac MRI, CT imaging, and AI-assisted diagnostic software to improve diagnostic accuracy and treatment planning. Increasing availability of high-resolution imaging systems supports earlier disease characterization while reducing diagnostic uncertainty. Comprehensive imaging capabilities strengthen multidisciplinary heart failure management across hospitals and specialty cardiac centers.

Technological Advancements in Diagnostic Platforms

• Diagnostic innovation continues improving analytical sensitivity, workflow automation, and digital integration across cardiovascular diagnostics. Manufacturers are introducing highly sensitive biomarker assays, portable point-of-care testing devices, and artificial intelligence-enabled imaging solutions that accelerate diagnosis without compromising clinical accuracy. Laboratory automation and digital reporting systems improve operational efficiency while supporting faster treatment decisions. These technological advancements reinforce the transition toward precision-based cardiovascular diagnostics.

Market Restraints

• High capital investment required for advanced cardiac imaging systems limits adoption among smaller healthcare facilities and resource-constrained regions. Variability in access to specialized cardiology services and imaging expertise creates disparities in diagnostic availability across healthcare systems. Reimbursement limitations for advanced diagnostic procedures restrict broader utilization despite increasing clinical evidence supporting comprehensive heart failure assessment. Additionally, the complexity of integrating multiple diagnostic modalities into cohesive clinical workflows can present operational challenges.

Technology and Segment Insights

By Diagnostic Test

• Natriuretic peptide testing (BNP and NT-proBNP) represents the largest diagnostic segment because these biomarkers remain the recommended standard for evaluating patients with suspected heart failure. Clinical guidelines continue supporting their routine use due to their ability to differentiate heart failure from non-cardiac causes of dyspnea and estimate disease severity. Cardiac troponin tests are increasingly utilized for risk stratification and to detect myocardial injury in heart failure patients. Echocardiography is the primary imaging modality for assessing cardiac structure and function, providing critical information on ejection fraction and valvular abnormalities. Electrocardiography (ECG) remains a fundamental screening tool. Cardiac magnetic resonance imaging (MRI) offers superior tissue characterization for complex cases. Computed tomography (CT) and chest X-ray provide complementary anatomical information. Point-of-care heart failure testing is gaining adoption because rapid biomarker assessment supports immediate clinical decision-making in emergency and outpatient settings.

By Technology

• Immunoassays dominate the technology landscape because they provide highly sensitive and standardized quantification of natriuretic peptides and cardiac troponins. Clinical chemistry analyzers support broad laboratory testing capabilities. Molecular diagnostics are emerging for advanced risk assessment. Ultrasound imaging systems, including advanced echocardiography platforms, are essential for structural and functional assessment. AI-enabled diagnostic platforms are increasingly integrated to improve interpretation consistency and workflow efficiency.

By End User

• Hospitals represent the largest end-user segment because they manage acute heart failure admissions, emergency cardiovascular care, and long-term disease monitoring. Healthcare institutions are expanding laboratory automation and advanced imaging capabilities to improve diagnostic efficiency and patient outcomes. Diagnostic laboratories are increasing biomarker testing capacity. Cardiology clinics are adopting integrated diagnostic pathways for outpatient management. Ambulatory care centers and academic research institutes contribute to the market through specialized services and clinical innovation.

Competitive and Strategic Outlook

• The competitive landscape features major diagnostic and imaging companies with strong cardiovascular portfolios. F. Hoffmann-La Roche Ltd. maintains a leading position through its comprehensive cardiovascular biomarker portfolio, including Elecsys immunoassays for NT-proBNP and cardiac troponins, supported by automated cobas analyzers. Abbott Laboratories differentiates itself through a broad portfolio of cardiovascular biomarkers, automated immunoassay systems (Alinity and ARCHITECT), and point-of-care technologies. Siemens Healthineers AG integrates laboratory medicine, advanced imaging, and digital health technologies, including Atellica laboratory systems and advanced cardiac imaging platforms. Beckman Coulter, Inc. (Danaher Corporation) focuses on high-performance clinical chemistry and immunoassay systems for large-scale cardiovascular testing. bioMerieux SA leverages its in vitro diagnostics expertise for laboratory automation. QuidelOrtho Corporation combines immunodiagnostics with point-of-care and centralized testing capabilities. Fujirebio Holdings specializes in high-quality immunoassay development. Sysmex Corporation integrates laboratory diagnostics, automation, and digital healthcare solutions.
• Strategic developments include increasing integration of AI with cardiac imaging and laboratory diagnostics, expansion of point-of-care testing, and development of integrated diagnostic pathways. Companies are forming collaborations with healthcare providers and research institutions to validate novel biomarkers and improve clinical adoption. Product launches focus on high-sensitivity assays, automated laboratory systems, and AI-enabled imaging software. Companies that successfully combine biomarker testing, advanced imaging, and digital health solutions into comprehensive diagnostic ecosystems are expected to strengthen their competitive positions.

Conclusion

• The heart failure diagnostics market is poised for substantial growth, driven by the rising prevalence of cardiovascular disease and the shift toward integrated, biomarker-guided diagnostic pathways. The evolution from symptom-based evaluation toward comprehensive diagnostic strategies combining biomarkers, advanced imaging, and digital tools is reshaping clinical practice. Companies that successfully develop integrated diagnostic solutions with strong clinical evidence and global reach are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding healthcare infrastructure across emerging economies will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Heart Failure Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2031)
• 3.7 Heart Failure Classification
• 3.8 Disease Burden & Unmet Clinical Needs
• 3.9 Epidemiology & Prevalence Analysis
• 3.10 Diagnosed Patient Population Analysis
• 3.11 Diagnostic Testing Volume Analysis
• 3.12 Heart Failure Diagnostic Pathway

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Diagnostic Technologies
• 6.2 Product Innovation
• 6.3 Biomarker Innovation
• 6.4 AI Integration in Heart Failure Diagnosis
• 6.5 Digital Health Integration
• 6.6 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Heart Failure Diagnostics Market Landscape Analysis

• 8.1 Analysis by Diagnostic Modality
• 8.2 Analysis by Biomarker
• 8.3 Analysis by Technology Platform
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by End User

9. Heart Failure Diagnostics Market Segment Analysis (2021-2031)

• 9.1 By Diagnostic Test
  • 9.1.1 Natriuretic Peptide Tests (BNP & NT-proBNP)
  • 9.1.2 Cardiac Troponin Tests
  • 9.1.3 Echocardiography
  • 9.1.4 Electrocardiography (ECG)
  • 9.1.5 Cardiac Magnetic Resonance Imaging (Cardiac MRI)
  • 9.1.6 Computed Tomography (CT)
  • 9.1.7 Chest X-ray
  • 9.1.8 Point-of-Care Heart Failure Testing
• 9.2 By Technology
  • 9.2.1 Immunoassays
  • 9.2.2 Clinical Chemistry Analyzers
  • 9.2.3 Molecular Diagnostics
  • 9.2.4 Ultrasound Imaging Systems
  • 9.2.5 AI-enabled Diagnostic Platforms
• 9.3 By End User
  • 9.3.1 Hospitals
  • 9.3.2 Diagnostic Laboratories
  • 9.3.3 Cardiology Clinics
  • 9.3.4 Ambulatory Care Centers
  • 9.3.5 Academic & Research Institutes

10. Heart Failure Diagnostics Market Geographical Analysis (2021-2031)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Heart Failure Diagnostics Market Country Analysis (2021-2031)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia
• 11.15 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
• 13.2 Abbott Laboratories
• 13.3 Siemens Healthineers AG
• 13.4 Beckman Coulter, Inc. (Danaher Corporation)
• 13.5 bioMerieux SA
• 13.6 QuidelOrtho Corporation
• 13.7 Fujirebio Holdings, Inc.
• 13.8 Sysmex Corporation
• 13.9 Becton, Dickinson and Company (BD)
• 13.10 Thermo Fisher Scientific Inc.
• 13.11 Quest Diagnostics Incorporated
• 13.12 Labcorp Holdings Inc.
• 13.13 Koninklijke Philips N.V.
• 13.14 GE HealthCare Technologies Inc.
• 13.15 Canon Medical Systems Corporation

14. Heart Failure Diagnostics Market Commercial Forecast Analysis

• 14.1 Natriuretic Peptide Tests (BNP & NT-proBNP)
• 14.2 Cardiac Troponin Tests
• 14.3 Echocardiography
• 14.4 Electrocardiography (ECG)
• 14.5 Cardiac Magnetic Resonance Imaging (Cardiac MRI)
• 14.6 Point-of-Care Heart Failure Testing

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends